4.5 Article

Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021

Journal

EUROSURVEILLANCE
Volume 26, Issue 29, Pages -

Publisher

EUR CENTRE DIS PREVENTION & CONTROL
DOI: 10.2807/1560-7917.ES.2021.26.29.2100670

Keywords

-

Funding

  1. European Union [101003673]

Ask authors/readers for more resources

A study conducted in eight European countries found that COVID-19 vaccines provide good protection against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults aged 65 and older, with particularly significant effectiveness observed in fully vaccinated individuals.
We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults >= 65 years old using a multicentre test-negative design in eight European countries. We included 592 SARS-CoV-2 cases and 4,372 test-negative controls in the main analysis. The VE was 62% (95% CI: 45-74) for one dose only and 89% (95% CI: 79-94) for complete vaccination. COVID-19 vaccines provide good protection against COVID-19 presentation at primary care/outpatient level, particu-larly among fully vaccinated individuals.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available